FDA approves needle-free insulin for children

The FDA approved Afrezza, a needle-free inhaled insulin, for use in children, expanding the drug's addressable patient base beyond adults. The decision is a positive regulatory milestone for the diabetes treatment and could support adoption if efficacy and convenience resonate with pediatric patients and caregivers. The article does not provide pricing, sales, or stock reaction details.

Analysis

The FDA approved Afrezza, a needle-free inhaled insulin, for use in children, expanding the drug's addressable patient base beyond adults. The decision is a positive regulatory milestone for the diabetes treatment and could support adoption if efficacy and convenience resonate with pediatric patients and caregivers. The article does not provide pricing, sales, or stock reaction details.